This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, D. Articles by Dou, Q. P. Search for Related Content PubMed PubMed Citation Articles by Chen, D. Articles by Dou, Q. P.

Clioquinol, a Therapeutic Agent for Alzheimer's Disease, Has Proteasome-Inhibitory, Androgen Receptor–Suppressing, Apoptosis-Inducing, and Antitumor Activities in Human Prostate Cancer Cells and Xenografts

¹ Barbara Ann Karmanos Cancer Institute and ² Department of Pathology, School of Medicine, Wayne State University; ³ Vattikuti Urology Institute, Henry Ford Hospital, Detroit, Michigan; ⁴ Biophysics Collaborative Access Team, Department of Biological Chemical and Physical Sciences, Illinois Institute of Technology, Chicago, Illinois; and ⁵ School of Pharmaceutical Sciences and Institute of Environmental Sciences, Shandong University, Jinan, Shandong, PR China

Requests for reprints: Q. Ping Dou, The Prevention Program, Barbara Ann Karmanos Cancer Institute, and Department of Pathology, School of Medicine, Wayne State University, 640.1 HWCRC, 4100 John R Road, Detroit, MI 48201. Phone: 313-576-8301; Fax: 313-576-8307; E-mail: doup{at}karmanos.org.

Tumor growth and metastasis depend on angiogenesis that requires the cofactor copper. Consistently, high levels of copper have been found in many types of human cancers, including prostate, breast, colon, and lung. Recent studies suggest that copper could be used as a novel selective target for cancer therapies. Clioquinol is capable of forming stable complexes with copper and currently used in clinics for treatment of Alzheimer's disease. Most recently, it has been reported that clioquinol possesses antitumor effects. However, the underlying molecular mechanism is unclear. We report here that after binding to copper, clioquinol can inhibit the proteasomal chymotrypsin-like activity, repress androgen receptor (AR) protein expression, and induce apoptotic cell death in human prostate cancer LNCaP and C4-2B cells. In addition, clioquinol alone exhibits similar effects in prostate cancer cell lines with elevated copper at concentrations similar to those found in patients. Addition of dihydrotestosterone did not affect clioquinol-mediated proteasome inhibition in both prostate cancer cell lines. However, dihydrotestosterone partially inhibited clioquinol-induced AR suppression and apoptosis only in androgen-dependent LNCaP cells. Animal studies show that clioquinol treatment significantly inhibits the growth of human prostate tumor C4-2B xenografts (by 66%), associated with in vivo proteasome inhibition, AR protein repression, angiogenesis suppression, and apoptosis induction. Our study provides strong evidence that clioquinol is able to target tumor proteasome in vivo in a copper-dependent manner, resulting in formation of an active AR inhibitor and apoptosis inducer that is responsible for its observed antiprostate tumor effect. [Cancer Res 2007;67(4):1636–44]

This article has been cited by other articles:

				Y. Wang, R. Branicky, Z. Stepanyan, M. Carroll, M.-P. Guimond, A. Hihi, S. Hayes, K. McBride, and S. Hekimi The Anti-neurodegeneration Drug Clioquinol Inhibits the Aging-associated Protein CLK-1 J. Biol. Chem., January 2, 2009; 284(1): 314 - 323. [Abstract] [Full Text] [PDF]

				T. Du, G. Filiz, A. Caragounis, P. J. Crouch, and A. R. White Clioquinol Promotes Cancer Cell Toxicity through Tumor Necrosis Factor {alpha} Release from Macrophages J. Pharmacol. Exp. Ther., January 1, 2008; 324(1): 360 - 367. [Abstract] [Full Text] [PDF]

				D. Chen, M. Frezza, R. Shakya, Q. C. Cui, V. Milacic, C. N. Verani, and Q. P. Dou Inhibition of the Proteasome Activity by Gallium(III) Complexes Contributes to Their Anti Prostate Tumor Effects Cancer Res., October 1, 2007; 67(19): 9258 - 9265. [Abstract] [Full Text] [PDF]